"Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer" was originally created and published by Pharmaceutical ...

Xepi is indicated for the topical treatment of impetigo due to S. aureus or S. pyogenes in adult and pediatric patients. The Food and Drug Administration (FDA) has approved Xepi (ozenoxacin cream; ...

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment ...

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology ...

EXPERIMENTAL pyelonephritis in animals and clinical pyelonephritis in man have been under serious investigation at Columbia Presbyterian Medical Center for the past decade. We have been publishing and ...

AbbVie announced that the US Food and Drug Administration (FDA) approved Dalvance (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients ...

The bacteria Staphylococcus aureus and Streptococcus pyogenes use fibronectin-binding proteins (FnBPs) anchored in their cell walls to adhere and invade host cells, but how the largely unstructured Fn ...

Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from ...

The Food and Drug Administration has approved Dalvance (dalbavancin), an antibacterial drug used to treat adults with bacterial skin and skin structure infections. Among them are infections caused by ...

THE effect of metals on the growth of bacteria has been examined by Miller, Behring, and others, and another t contribution to this subject has lately been published by Dr. Meade Bolton, in the ...